FLASH in Clinical and Preclinical Settings provides an update on the main preclinical data that have demonstrated how FLASH is able to conserve normal tissues enhancing anticancer potency, and on first in human data and on-going clinical trials.

The sessions also look at how to design adequate clinical trials and at additional clinical benefits of reducing treatment time, eventually limiting organ motion, increasing compliance of the patients, and increasing the number of patients that could be treated.